Kura Oncology Announces First-In-Human Data From The FIT-001 Clinical Trial Of Darlifarnib In Combination With Adagrasib In Heavily Pretreated Patients With KRAS G12C-Mutated Advanced Solid Tumors

Kura Oncology

Kura Oncology

KURA

0.00

– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients –

– ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients –

– Results reinforce darlifarnib's potential as a precision combination agent across targeted therapies –

– Clear clinical activity in KRASi-experienced patients and manageable safety profile –

– Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET –

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.